| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Antibiotics for COPD exacerbations
|
Labaki, Wassim W
|
|
2017
|
5 |
6 |
p. 461-462
2 p.
|
artikel
|
| 2 |
Clinical trial research in focus: time to reflect on the design of exacerbation trials in COPD
|
Vestbo, Jørgen
|
|
2017
|
5 |
6 |
p. 466-468
3 p.
|
artikel
|
| 3 |
Clinical trials in acute respiratory distress syndrome: challenges and opportunities
|
Matthay, Michael A
|
|
2017
|
5 |
6 |
p. 524-534
11 p.
|
artikel
|
| 4 |
Corrections
|
|
|
2017
|
5 |
6 |
p. e22-
1 p.
|
artikel
|
| 5 |
Corrections
|
|
|
2017
|
5 |
6 |
p. e22-
1 p.
|
artikel
|
| 6 |
Corrections
|
|
|
2017
|
5 |
6 |
p. e22-
1 p.
|
artikel
|
| 7 |
David Ashbaugh reminisces
|
Ashbaugh, David
|
|
2017
|
5 |
6 |
p. 474-
1 p.
|
artikel
|
| 8 |
Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial
|
van Velzen, Patricia
|
|
2017
|
5 |
6 |
p. 492-499
8 p.
|
artikel
|
| 9 |
Effect of early supplemental parenteral nutrition in the paediatric ICU: a preplanned observational study of post-randomisation treatments in the PEPaNIC trial
|
Vanhorebeek, Ilse
|
|
2017
|
5 |
6 |
p. 475-483
9 p.
|
artikel
|
| 10 |
Hard to say goodbye
|
van Dorn, Aaron
|
|
2017
|
5 |
6 |
p. 473-474
2 p.
|
artikel
|
| 11 |
Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study
|
Beigel, John H
|
|
2017
|
5 |
6 |
p. 500-511
12 p.
|
artikel
|
| 12 |
Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial
|
McAuley, Daniel F
|
|
2017
|
5 |
6 |
p. 484-491
8 p.
|
artikel
|
| 13 |
Keratinocyte growth factor in acute respiratory distress syndrome
|
Vadász, István
|
|
2017
|
5 |
6 |
p. 459-460
2 p.
|
artikel
|
| 14 |
Latin America makes progress on tobacco control
|
Burki, Talha Khan
|
|
2017
|
5 |
6 |
p. 470-
1 p.
|
artikel
|
| 15 |
Mesenchymal stem cell treatment for IPF—time for phase 2 trials?
|
Antoniou, Katerina M
|
|
2017
|
5 |
6 |
p. 472-473
2 p.
|
artikel
|
| 16 |
Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome
|
Meyer, Nuala J
|
|
2017
|
5 |
6 |
p. 512-523
12 p.
|
artikel
|
| 17 |
Protein provision in the critically ill child: is less more?
|
Ong, Chengsi
|
|
2017
|
5 |
6 |
p. 458-459
2 p.
|
artikel
|
| 18 |
Reappraisal of the clinical effect of mepolizumab
|
Lipworth, Brian J
|
|
2017
|
5 |
6 |
p. e20-
1 p.
|
artikel
|
| 19 |
Reappraisal of the clinical effect of mepolizumab – Authors' reply
|
Chupp, Geoffrey L
|
|
2017
|
5 |
6 |
p. e21-
1 p.
|
artikel
|
| 20 |
Respiratory medicine and critical care: a call for papers for ERS
|
Feetham, Laura
|
|
2017
|
5 |
6 |
p. 468-
1 p.
|
artikel
|
| 21 |
Serotherapy for patients with severe influenza
|
Scott, Dorothy
|
|
2017
|
5 |
6 |
p. 462-464
3 p.
|
artikel
|
| 22 |
The NHS is no place for immigration enforcement
|
The Lancet Respiratory Medicine,
|
|
2017
|
5 |
6 |
p. 457-
1 p.
|
artikel
|
| 23 |
Thomas L Petty
|
Akkermans, Rebecca
|
|
2017
|
5 |
6 |
p. 471-472
2 p.
|
artikel
|
| 24 |
UK Government must publish air pollution strategy
|
Burki, Talha Khan
|
|
2017
|
5 |
6 |
p. 469-
1 p.
|
artikel
|
| 25 |
US drug shortages might have led to more patient deaths
|
Furlow, Bryant
|
|
2017
|
5 |
6 |
p. 469-
1 p.
|
artikel
|
| 26 |
Whose advance directives are they, after all?
|
Brown, Samuel M
|
|
2017
|
5 |
6 |
p. 464-466
3 p.
|
artikel
|
Tijdschrift beschrijving